US Patent No: 7,384,653

Number of patents in Portfolio can not be more than 2000

Oral dosage form comprising a therapeutic agent and an adverse-effect agent

Stats

ALSO PUBLISHED AS: 20050063909
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is covered with a coating that is substantially insoluble in the gastrointestinal tract. In one embodiment, the adverse-effect agent is coated with an outer base-soluble layer and an inner acid-soluble layer. The therapeutic agent can be uncoated or can be coated with a coating having an outer acid-soluble layer and an inner base-soluble layer. The dosage form discourages administration of the therapeutic agent by other than oral administration.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
PURDUE PHARMA L.P.STAMFORD, CT215

International Classification(s)

  • No International Classification to display

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Carpanzano, Anthony E Sherman, CT 7 94
Wright, IV Curtis Norwalk, CT 1 6

Cited Art

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (37)
4,828,836 Controlled release pharmaceutical composition 127 1987
4,834,985 Controlled release pharmaceutical composition 160 1987
4,990,341 Controlled release hydromorphone composition 84 1989
5,266,331 Controlled release oxycodone compositions 92 1991
5,273,760 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 124 1991
5,286,493 Stabilized controlled release formulations having acrylic polymer coating 125 1992
5,549,912 Controlled release oxycodone compositions 80 1993
5,472,712 Controlled-release formulations coated with aqueous dispersions of ethylcellulose 109 1993
5,580,578 Controlled release formulations coated with aqueous dispersions of acrylic polymers 97 1993
5,478,577 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level 82 1993
5,411,745 Powder-layered morphine sulfate formulations 60 1994
5,965,161 Extruded multi-particulates 60 1994
5,639,476 Controlled release formulations coated with aqueous dispersions of acrylic polymers 234 1995
5,508,042 Controlled release oxycodone compositions 80 1995
5,968,551 Orally administrable opioid formulations having extended duration of effect 88 1995
5,958,459 Opioid formulations having extended controlled released 51 1995
5,656,295 Controlled release oxycodone compositions 67 1996
5,681,585 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 56 1996
5,672,360 Method of treating pain by administering 24 hour oral opioid formulations 89 1996
6,143,322 Method of treating humans with opioid formulations having extended controlled release 63 1997
5,958,452 Extruded orally administrable opioid formulations 76 1997
5,968,547 Method of providing sustained analgesia with buprenorphine 45 1997
6,077,533 Powder-layered oral dosage forms 36 1998
6,228,863 Method of preventing abuse of opioid dosage forms 69 1998
6,277,384 Opioid agonist/antagonist combinations 48 1998
6,103,261 Opioid formulations having extended controlled release 51 1999
6,335,033 Melt-extrusion multiparticulates 40 1999
6,261,599 Melt-extruded orally administrable opioid formulations 63 1999
6,294,195 Orally administrable opioid formulations having extended duration of effect 63 1999
6,375,957 Opioid agonist/opioid antagonist/acetaminophen combinations 59 2000
6,696,088 Tamper-resistant oral opioid agonist formulations 46 2001
6,475,494 Opioid agonist/antagonist combinations 36 2001
7,141,250 Pharmaceutical formulation containing bittering agent 14 2002
7,144,587 Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent 23 2002
6,696,066 Opioid agonist/antagonist combinations 35 2002
7,172,767 Opioid agonist / antagonist combinations 19 2003
2007/0014,732 Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent 18 2006
 
EURO-CELTIQUE S.A. (35)
4,366,310 Controlled release compositions 27 1980
4,940,587 Oral pharmaceutical composition through mucosa 71 1986
4,844,907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 97 1986
4,834,965 Controlled release pharmaceutical composition 58 1987
4,867,985 Spheroids 63 1988
5,071,646 Pharmaceutical ion exchange resin composition 73 1989
5,091,189 Controlled release dosage forms having a defined water content 24 1991
5,215,758 Controlled release matrix suppository for pharmaceuticals 54 1991
5,324,351 Aqueous dispersions of zein and preparation thereof 62 1992
5,356,467 Controlled release coatings derived from aqueous dispersions of zein 92 1993
5,500,227 Immediate release tablet cores of insoluble drugs having sustained-release coating 93 1993
5,622,722 Spheroid formulation 24 1994
5,508,043 Controlled release matrix for pharmaceuticals 31 1995
5,670,172 Pharmaceutical spheroid formulation 44 1995
6,024,982 Immediate release tablet cores of insoluble drugs having sustained-release coating 53 1995
5,811,126 Controlled release matrix for pharmaceuticals 49 1995
5,763,452 Pharmaceutical compositions and usages 23 1996
5,849,240 Method of preparing sustained release pharmaceutical compositions 59 1996
5,891,471 Pharmaceutical multiparticulates 50 1996
5,601,845 Pharmaceutical spheroid formulation 55 1996
5,843,480 Controlled release diamorphine formulation 41 1996
5,879,705 Sustained release compositions of morphine and a method of preparing pharmaceutical compositions 54 1997
5,908,848 Synergistic composition of codine and ibuprofen to treat arthritis 24 1997
5,942,241 Formulations and methods for providing prolonged local anesthesia 76 1997
6,068,855 Pharmaceutical composition containing a fusible carrier and method for producing the same 38 1997
5,965,163 Substained release compositions and a method of preparing pharmaceutical compositions 58 1997
6,077,532 Pharmaceutical ion exchange resin composition 30 1998
6,306,438 Stabilized sustained release tramadol formulations 37 1998
6,399,096 Pharmaceutical formulation 30 1998
6,143,328 Sustained release compositions and a method of preparing pharmaceutical compositions 27 1999
6,162,467 Sustained release compositions and a method of preparing pharmaceutical compositions 41 1999
6,210,714 Immediate release tablet cores of acetaminophen having sustained-release coating 34 2000
6,387,404 Immediate release tablet cores of insoluble drugs having sustained-release coating 34 2001
6,716,449 Controlled-release compositions containing opioid agonist and antagonist 37 2001
6,627,635 Method of preventing abuse of opioid dosage forms 41 2001
 
ALZA CORPORATION (6)
4,200,098 Osmotic system with distribution zone for dispensing beneficial agent 263 1978
4,285,987 Process for manufacturing device with dispersion zone 240 1979
4,573,995 Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine 103 1984
5,236,714 Abusable substance dosage form having reduced abuse potential 57 1988
5,460,826 Morphine therapy 59 1994
5,866,164 Composition and dosage form comprising opioid antagonist 68 1997
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (6)
4,401,672 Non-addictive narcotic antitussive preparation 41 1981
4,730,048 Gut-selective opiates 50 1985
5,352,680 Delta opioid receptor antagonists to block opioid agonist tolerance and dependence 67 1992
5,457,208 Kappa opioid receptor antagonists 52 1993
5,578,725 Delta opioid receptor antagonists 35 1995
5,780,479 Use of opioid antagonists to treat impulse-control disorders 29 1997
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (5)
5,512,578 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists 62 1994
5,624,932 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 29 1995
RE36547 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists 27 1996
5,767,125 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 47 1996
6,096,756 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 34 1998
 
MERCK FROSST CANADA & CO. (5)
5,436,265 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents 59 1993
5,521,213 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 70 1994
5,536,752 Phenyl heterocycles as COX-2 inhibitors 54 1995
5,550,142 Phenyl heterocycles as cox-2 inhibitors 61 1995
5,639,780 N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors 48 1995
 
MERCK FROSST CANADA LTD. (5)
5,409,944 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase 47 1993
5,604,260 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 58 1993
5,552,422 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents 77 1995
5,510,368 N-benzyl-3-indoleacetic acids as antiinflammatory drugs 65 1995
5,604,253 N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors 50 1995
 
SCHAAP; ROBERT J. (4)
5,316,759 Agonist-antagonist combination to reduce the use of nicotine and other drugs 43 1992
5,935,975 Agonist-antagonist combination to reduce the use of nicotine and other drugs 16 1993
5,574,052 Agonist-antagonist combination to reduce the use of nicotine and other drugs 87 1994
5,703,101 Agonist-antagonist combination to reduce the use of nicotine and other drugs 10 1995
 
UNIVERSITY OF CHICAGO, THE (4)
4,719,215 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 52 1986
4,861,781 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 47 1987
5,102,887 Method for reducing emesis and nausea induced by the administration of an emesis causing agent 49 1990
5,972,954 Use of methylnaltrexone and related compounds 57 1997
 
VIRGINIA COMMONWEALTH UNIVERSITY (4)
5,352,683 Method for the treatment of chronic pain 61 1993
5,321,012 Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance 92 1993
5,502,058 Method for the treatment of pain 71 1994
5,556,838 Inhibiting the development of tolerance to and/or dependence on an addictive substance 85 1994
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (3)
5,472,943 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists 49 1993
5,585,348 Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia 44 1993
5,580,876 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 49 1995
 
CONTRAL CLINICS OY (3)
4,882,335 Method for treating alcohol-drinking response 53 1988
5,096,715 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist 39 1989
5,086,058 Method for treating alcoholism with nalmefene 51 1990
 
NAPP PHARMACEUTICAL GROUP LIMITED (3)
5,591,452 Controlled release formulation 50 1994
6,326,027 Controlled release formulation 37 1995
6,254,887 Controlled release tramadol 35 1996
 
THE ROCKEFELLER UNIVERSITY (3)
4,987,136 Method for controlling gastrointestinal dysmotility 80 1986
4,769,372 Method of treating patients suffering from chronic pain or chronic cough 57 1986
4,785,000 Method of treating patients suffering from chronic pain or chronic cough 39 1987
 
ASTELLAS PHARMA INC. (2)
6,368,629 Colon-specific drug release system 23 1998
6,506,407 Colon-specific drug release system 12 2001
 
BASF AKTIENGESELLSCHAFT (2)
4,806,558 Diarylacetylenes and their use in treating acne 34 1985
4,957,681 Preparation of pharmaceutical mixtures 65 1989
 
E. I. DU PONT DE NEMOURS AND COMPANY (2)
4,451,470 Analgesic, antagonist, and/or anorectic 14-fluoromorphinans 41 1982
5,593,994 Prostaglandin synthase inhibitors 43 1994
 
EDT PHARMA HOLDINGS (2)
6,228,398 Multiparticulate modified release composition 63 2000
6,902,742 Multiparticulate modified release composition 15 2002
 
ELI LILLY AND COMPANY (2)
4,293,539 Controlled release formulations and method of treatment 74 1979
5,998,434 Composition for treating pain 28 1998
 
ENDO PHARMACEUTICALS INC. (2)
2003/0064,122 Abuse resistant pharmaceutical composition containing capsaicin 20 2002
2003/0004,177 Abuse-resistant opioid dosage form 52 2002
 
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURG (2)
4,844,909 Controlled release hydromorphone composition 78 1987
4,844,910 Spheroids 33 1987
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (2)
5,290,816 Composition of resiniferatoxin and analogues thereof to cause sensory afferent C-Fiber and thermoregulatory desensitization 16 1990
5,225,440 Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase 37 1991
 
NORWICH EATON PHARMACEUTICALS, INC. (2)
4,798,725 Sustained release capsule 24 1986
5,026,556 Compositions for the transdermal delivery of pharmaceutical actives 24 1988
 
NOVA PHARMACEUTICAL CORPORATION (2)
4,760,069 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 44 1985
4,889,860 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 48 1987
 
OMEROS CORPORATION (2)
5,858,017 Urologic irrigation solution and method for inhibition of pain, inflammation and spasm 81 1996
5,860,950 Arthroscopic irrigation solution and method for inhibition of pain and inflammation 65 1996
 
ORTHO-MCNEIL PHARMACEUTICAL, INC. (2)
5,069,909 Transdermal administration of buprenorphine 54 1990
5,336,691 Composition comprising a tramadol material and acetaminophen and its use 39 1992
 
PURDUE PHARMA COMPANY, THE (2)
4,861,598 Controlled release bases for pharmaceuticals 96 1986
4,970,075 Controlled release bases for pharmaceuticals 75 1989
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (2)
4,582,835 Analgesic compositions 62 1984
4,661,492 Analgesic compositions 47 1985
 
THE PROCTER & GAMBLE COMPANY (2)
4,424,205 Hydroxyphenylacetamides having analgesic and anti-irritant activity 27 1982
4,812,446 Pharmaceutical products providing enhanced analgesia 21 1987
 
AB FERROSAN CELSIUSGATAN 35, 201 10 MALMO 1, SWEDEN, (1)
4,385,057 Diphenylbutyl-piperazinecarboxamides in pharmaceutical compositions and methods 12 1981
 
ACURA PHARMACEUTICALS, INC. (1)
7,201,920 Methods and compositions for deterring abuse of opioid containing dosage forms 17 2003
 
ADIR ET COMPAGNIE (1)
5,130,311 Oxazolopyridine compounds, compositions and use 29 1991
 
AMINOTEK SCIENCES, INC. (1)
5,256,669 Methods and compositions for treating acute or chronic pain and drug addiction 39 1992
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
4,873,076 Method of safely providing anesthesia or conscious sedation 38 1989
 
BRISTOL-MYERS COMPANY (1)
4,457,933 Prevention of analgesic abuse 62 1981
 
BRITISH TECHNOLOGY GROUP LIMITED (1)
4,738,973 Pharmaceutical compositions and medical uses of dioxopiperidine derivatives 6 1986
 
BURLINGTON BIO-MEDICAL & SCIENTIFIC CORP. (1)
5,891,919 Denatonium capsaicinate and methods of producing the same 17 1997
 
COLMAN PRODUCTS LIMITED (1)
4,935,428 Treating opiate dependence 50 1988
 
DUPONT PHARMACEUTICALS COMPANY (1)
4,237,140 Analgesic mixture of nalbuphine and acetaminophen 36 1979
 
DYNAGEN, INC. (1)
5,486,362 Controlled, sustained release delivery system for treating drug dependency 66 1993
 
EMORY UNIVERSITY (1)
5,762,963 Method and compositions for controlling oral and pharyngeal pain using capsaicinoids 24 1995
 
ENCINAL PHARMACEUTICAL INVESTMENTS, LLC (1)
5,869,097 Method of therapy comprising an osmotic caplet 38 1992
 
G. D. SEARLE & CO. (1)
5,616,601 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation 94 1995
 
GENERAL ELECTRIC COMPANY (1)
5,226,331 Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream 29 1991
 
GRUENENTHAL GMBH (1)
2005/0214,223 Abuse-safeguarded dosage form 21 2005
 
ICN HUNGARY RT. (1)
5,317,022 Pharmaceutical composition and use 39 1992
 
KEY PHARMACEUTICALS, INC. (1)
4,587,118 Dry sustained release theophylline oral formulation 41 1984
 
LTS LOHMANN THERAPIE-SYSTEME GMBH (1)
5,240,711 Transdermal therapeutic system comprising as active component buprenorphine 28 1992
 
MCGINNIS; CAROLYN (1)
4,608,376 Opiate agonists and antagonists 32 1982
 
MERCK FROSST COMPANY (1)
5,474,995 Phenyl heterocycles as cox-2 inhibitors 127 1994
 
MERCK SHARP & DOHME LTD. (1)
5,880,132 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception 38 1997
 
OREGON, UNIVERSITY OF (1)
5,514,680 Glycine receptor antagonists and the use thereof 44 1993
 
PEPTECH LIMITED (1)
5,534,492 Muramyl peptide for the treatment of toxicity 29 1995
 
PUREUE PHARMA L.P. (1)
4,834,984 Controlled release dihydrocodeine composition 73 1987
 
RECKITT BENCKISER (UK) LIMITED (1)
6,582,484 Candle composition 2 2001
 
RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE, OLD QUEEN BUILDING, SOMERSET AND GEORGE STREETS, NEW BRUNSWICK, NJ 08903 (1)
4,806,341 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration 71 1986
 
SANDOZ LTD. (1)
5,403,868 Capsaicin derivatives 15 1994
 
SCULLY SCOTT MURPHY & PRESSER, PC (1)
5,426,112 Growth regulation and related applications of opioid antagonists 49 1993
 
SIMON, DAVID L. (1)
6,103,258 Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics 26 1998
 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (1)
4,803,208 Opiate agonists and antagonists 36 1985
 
SUPERNUS PHARMACEUTICALS, INC (1)
2004/0228,802 Drug formulations having reduced abuse potential 20 2003
 
TEIJIN LIMITED (1)
5,225,199 Pharmaceutical plasters 33 1991
 
TEIKOKU PHARMA USA, INC. (1)
2005/0163,717 Abuse potential reduction in abusable substance dosage form 13 2004
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
4,806,543 Method and compositions for reducing neurotoxic injury 58 1986
 
THE MCLEAN HOSPITAL CORPORATION (1)
5,075,341 Treatment for cocaine abuse 87 1989
 
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (1)
5,834,477 Opiate analgesic formulation with improved safety 24 1994
 
TRANSCONTINENTAL MARKETING GROUP, INC. (1)
5,376,705 One coat protective system for a surface 14 1993
 
UNITED BIOMEDICAL, INC. (1)
5,633,259 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 31 1995
 
WARNER-LAMBERT COMPANY (1)
5,149,538 Misuse-resistive transdermal opioid dosage form 98 1991
 
YOUNG, JACQUELINE, MS. (1)
5,356,900 Method of treating chronic herpes virus infections using an opiate receptor antagonist 37 1993
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (5)
4,464,378 Method of administering narcotic antagonists and analgesics and novel dosage forms containing same 108 1981
4,443,428 Extended action controlled release compositions 53 1982
5,376,662 Method of attenuating nerve injury induced pain 34 1993
2003/0059,471 Oral delivery formulation 51 2001
2003/0026,838 Tamper-proof narcotic delivery system 15 2002

Patent Citation Ranking

  • No Patent Citation Ranking to display

Forward Cites

Patent Info (Count) # Cites Year
 
ALPHARMA PHARMACEUTICALS, LLC (3)
8,158,156 Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist 0 2007
7,682,633 Pharmaceutical composition 0 2009
7,682,634 Pharmaceutical compositions 0 2009
 
ACURA PHARMACEUTICALS, INC. (2)
7,981,439 Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof 0 2008
8,409,616 Extended release opioid abuse deterrent compositions and methods of making same 0 2011
 
NANOTHERAPEUTICS, INC. (1)
8,377,479 Compositions and methods for delivery of poorly soluble drugs 0 2008

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 10, 2015
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 10, 2019
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00